Philippe Pouletty, a French trained medical doctor and general partner at Paris-based Truffle Capital has reason to look especially cheerful these days. Carmat, a company building an entirely artificial human heart, is planning an initial public offering in June - the  third company in Pouletty's portfolio to go public in as many months. Though no one expects 2010 to look like 1999 the market for IPOs - particularly in biotech - appears to be open once again.Read more